Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial

Kim CY, et al.: J Neurooncol. 2020 Feb;146（3）:399-406. doi: 10.1007/s11060-019-03361-2.

Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial

Toms SA, et al.: J Neurooncol. 2019 Jan;141（2）:467-473. doi: 10.1007/s11060-018-03057-z.

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial

Taphoorn MJB, et al.: JAMA Oncol. 2018 Apr 1;4（4）:495-504. doi: 10.1001/jamaoncol.2017.5082.

Efficacy and Safety of Tumor Treating Fields （TTFields） in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial

Ram Z, et al.: Front Oncol. 2021 Sep 27;11:671972. doi: 10.3389/fonc.2021.671972. eCollection 2021.

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma A Randomized Clinical Trial

Stupp R, et al.: JAMA. 2015 Dec 15;314（23）:2535-43. doi: 10.1001/jama.2015.16669.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma；A Randomized Clinical Trial

Stupp R, et al.: JAMA. 2017 Dec 19;318（23）:2306-2316. doi: 10.1001/jama.2017.18718.